Christopher Razavi

Christopher Razavi practices at Head and Neck Surgery Department of Otolaryngology in New York, New York.

Christopher Razavi's NPI, 1861809097, was assigned on July 21, 2014. Christopher Razavi holds Oregon license MD209425.

Christopher Razavi's primary practice is Head and Neck Surgery Department of Otolaryngology, at 234 E 85th St, New York, NY 10028 in New York County. The practice phone is (212) 241-9410.

Christopher Razavi's primary practice is Head and Neck Surgery Department of Otolaryngology in New York, New York. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Christopher Razavi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Christopher Razavi practices. Vendor and product names are available with a free account.

Facial plastic surgery is Christopher Razavi's primary specialty in the NPI Registry, under taxonomy code 207YS0123X. Dmand AI has Christopher Razavi's licenses on file in 2 states: Oregon and Maryland.

CMS data shows 105 Medicare services from Christopher Razavi across 5 procedure codes in 2024, for 67 Medicare patients. Medicare paid $18,161 for them. Every service was in an office.

CMS counts 67 Medicare patients who saw Christopher Razavi in 2024. The largest group is 65 to 74, with 30 patients. 72% of them have high cholesterol, and 70% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.19, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Christopher Razavi's median patient age at 41, with 46% women.

In 2024, Christopher Razavi wrote 36 Medicare Part D claims for 17 patients. 100% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $77 in total drug cost. In 2022, CMS named 14 claims across 1 drug.

Christopher Razavi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Christopher Razavi as offering telehealth. CMS counts 16 procedures of melanoma (skin cancer) excision by Christopher Razavi, more than 71% of the clinicians it reports for that procedure.

CMS Open Payments shows 32 general payments to Christopher Razavi from 10 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 67% of the total. Intuitive Surgical, Inc. paid the most, $1,164.